#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2144	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2626	241.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1689	1689	C	295	C,A	268,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3300	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4226	233.8	0	.	n	.	0	T695C	SNP	695	695	T	1359	1359	C	265	C,A	241,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3300	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4226	233.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	2001	2001	A	272	A	259	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3300	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4226	233.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2635	2635	C	296	C	268	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3300	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4226	233.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2709	2709	A	328	A,C	290,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3300	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4226	233.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3261	3261	C	273	C,T,A	233,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	340	folP	852	852	100.0	folP.l15.c4.ctg.1	2098	48.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1246	1248	AGC	77;79;79	A;G;C	69;72;71	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	650	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4007	48.7	1	SNP	p	S91F	0	.	.	271	273	TCC	960	962	TCC	60;60;60	T;C;C	55;55;55	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	650	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4007	48.7	1	SNP	p	D95N	0	.	.	283	285	GAC	972	974	GAC	61;61;63	G;A;C,T	56;55;55,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	650	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4007	48.7	1	SNP	p	D95G	0	.	.	283	285	GAC	972	974	GAC	61;61;63	G;A;C,T	56;55;55,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	244	246	ACT	17;17;17	A;C;T	14;14;13	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	D40A	NONSYN	118	120	GAC	247	249	GCC	17;17;17	G;C,A;C	14;12,1;14	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	R44H	NONSYN	130	132	CGC	259	261	CAC	20;20;20	C;A;C	16;17;17	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	I73M	NONSYN	217	219	ATC	346	348	ATG	21;21;21	A;T;G,C	20;18;18,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	A74S	NONSYN	220	222	GCG	349	351	TCG	21;21;21	T,G;C;G	16,1;19;19	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	Q75K	NONSYN	223	225	CAA	352	354	AAA	21;21;20	A,C;A;A	18,1;20;20	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	A77T	NONSYN	229	231	GCC	358	360	ACG	21;21;21	A,G;C;G,C	20,1;20;18,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	A78E	NONSYN	232	234	GCA	361	363	GAA	21;21;21	G;A,C;A	21;20,1;21	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	.	MULTIPLE	235	237	GAT	364	367	AATA	21;21;21;20	A,G;A;T;A	19,1;21;18;20	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	G83Q	NONSYN	247	249	GGG	379	381	CAA	21;21;21	C;A,G;A,T	20;20,1;19,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	A86V	NONSYN	256	258	GCG	388	390	GTA	21;21;21	G,A;T,C;A,G	20,1;20,1;18,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	H90R	NONSYN	268	270	CAC	400	402	CGT	21;21;21	C;G,A;T,C	19;20,1;19,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	N110S	NONSYN	328	330	AAC	460	462	AGC	22;22;22	A;G,A;C	21;21,1;22	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	0	.	p	.	0	V143F	NONSYN	427	429	GTT	559	561	TTT	21;20;20	T,G;T;T	15,1;15;16	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	528	58	mtrR	633	459	91.34	mtrR.l15.c17.ctg.1	598	19.9	1	SNP	p	G45D	0	.	.	133	135	GGC	262	264	GGC	20;20;20	G;G;C	16;17;17	mtrR.WHO_Z_01455:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	G27A	SNP	27	27	G	273	273	A	25	A,G	19,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	A123G	SNP	123	123	A	369	369	G	12	G,A	11,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	T128G	SNP	128	128	T	374	374	G	11	G,T	10,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	G141A	SNP	141	141	G	387	387	A	11	A,G	10,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	C147T	SNP	147	147	C	393	393	T	11	T,C	10,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	T159C	SNP	159	159	T	405	405	C	11	C,T	9,2	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	G163A	SNP	163	163	G	409	409	A	11	A,G	10,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	A183C	SNP	183	183	A	429	429	C	10	C	10	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	C189T	SNP	189	189	C	435	435	T	10	T	8	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	A192T	SNP	192	192	A	438	438	T	10	T	10	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	A195C	SNP	195	195	A	441	441	C	10	C	10	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	C201A	SNP	201	201	C	447	447	A	10	A	9	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	G221A	SNP	221	221	G	467	467	A	10	A	10	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	50	mtrR_promoter	250	242	92.98	mtrR_promoter.l6.c17.ctg.1	870	12.4	0	.	n	.	0	C231G	SNP	231	231	C	477	477	G	10	G	9	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	684	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3512	58.3	1	SNP	p	D86N	0	.	.	256	258	GAC	866	868	GAC	60;60;60	G;A;C	52;53;52	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	684	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3512	58.3	1	SNP	p	S87R	0	.	.	259	261	AGT	869	871	AGT	60;61;60	A;G;T	49;52;53	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	684	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3512	58.3	1	SNP	p	S87W	0	.	.	259	261	AGT	869	871	AGT	60;61;60	A;G;T	49;52;53	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	684	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3512	58.3	1	SNP	p	S87I	0	.	.	259	261	AGT	869	871	AGT	60;61;60	A;G;T	49;52;53	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	684	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3512	58.3	1	SNP	p	S88P	0	.	.	262	264	TCC	872	874	TCC	62;62;61	T;C;C	53;54;55	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	670	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3235	61.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1933	1935	GGC	68;67;65	G;G;C,A	62;63;58,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1466	1468	GCA	76;76;76	G;C;A,C	73;70;67,2	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1469	1471	ATC	76;76;76	A;T,G,C;C,G	70;68,1,1;71,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1481	1483	GTG	75;74;75	G,A;T,C;G,T,C	71,1;69,1;68,1,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1481	1483	GTG	75;74;75	G,A;T,C;G,T,C	71,1;69,1;68,1,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1985	1987	ACC	73;74;74	A,C;C;C	67,1;64;65	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2039	2041	GCG	74;74;75	G;C,G;G	68;61,1;61	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2039	2041	GCG	74;74;75	G;C,G;G	68;61,1;61	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2162	2164	GGC	72;71;71	G;G;C,A	64;65;65,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2171	2173	GGC	73;72;72	G;G;C	68;69;69	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	554	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2959	56.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2189	2191	CCG	75;74;74	C;C;G,A,C	67;64;61,1,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	720	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3831	56.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	334	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2452	40.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	910	910	C	54	C	48	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	416	418	GGA	107;107;107	G;G;A	97;95;98	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	677	679	CTT	83;83;82	C;T,C;T	77;68,1;68	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	701	703	GGA	79;79;79	G;G;A	72;70;70	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	785	787	GGT	77;77;77	G;G;T	71;70;68	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	839	841	AGC	77;78;78	A,G;G,C;C,A	69,1;71,1;70,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	905	905	T	84	T,C	70,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	1	SNP	p	G120K	0	.	.	358	360	GGT	632	634	GGT	89;88;88	G;G;T,A	83;78;81,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	1	SNP	p	A121D	0	.	.	361	363	GCC	635	637	GCC	88;88;88	G;C;C	82;79;84	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	442	porB1b	1035	1035	96.28	porB1b.l15.c30.ctg.1	1670	74.0	1	SNP	p	A121N	0	.	.	361	363	GCC	635	637	GCC	88;88;88	G;C;C	82;79;84	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1330	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5552	71.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2320	2322	AAT	74;74;74	A,C;A;T	65,1;67;69	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	216	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1568	41.3	1	SNP	p	V57M	1	.	.	169	171	ATG	763	765	ATG	84;84;85	A;T;G	75;75;75	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
